NavigAID for autoimmune disease
Autoimmune diseases are highly diverse, yet can cause similar symptoms in different patients, making accurate diagnoses and development of effective treatments difficult. Therefore, solving the problem of patient heterogeneity is pivotal for the clinical development of effective and potentially curative therapies.
One solution is to stratify patients based on the specific characteristics of their individual autoimmune disease, to enable accurate diagnoses and therapy response prediction during drug development, increasing the chances of treatment success.
Using its proprietary SeroTag® biomarker identification platform, Protagen has developed a pipeline of stratification arrays based on biomarker panels (NavigAID) to screen patient serum for an array of autoimmune diseases, such as Systemic Sclerosis (NavigAID SSc) and Systemic Lupus Erythematosus (NavigAID SLE). Additional NavigAID biomarker panels are under development for other autoimmune diseases, such as Rheumatoid arthritis and Sjögren’s syndrome.
By separating patients into disease subgroups NavigAID can:
- Assess the specific immunological processes underpinning the disease
- Improve response prediction to treatment and increase the chances of treatment success